Tambiciclib Triplet Shows Preliminary Activity After Venetoclax Failure

Company SELLAS Life Sciences Event Type Phase 2 data disclosure Modality Small molecule Asset Tambiciclib (SLS009) with azacitidine and venetoclax Target CDK9 Disease Area Relapsed or refractory AML Summary SELLAS disclosed Phase 2 results on November 4 for tambiciclib (SLS009) with azacitidine and venetoclax in…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Genentech / Astex | Breast Cancer Discovery Collaboration Amid gRED Restructuring
Sobi Licenses Lacutamab in $580 Million Deal
Moonwalk Raises $70 Million for Adipose-Targeted RNAi
Novo Licenses Hengrui Once-Weekly Oral Incretin